Brokerages expect Mediwound Ltd (NASDAQ:MDWD) to report earnings of ($0.15) per share for the current fiscal quarter, according to Zacks. Three analysts have provided estimates for Mediwound’s earnings, with the lowest EPS estimate coming in at ($0.19) and the highest estimate coming in at ($0.11). Mediwound reported earnings per share of ($0.11) during the same quarter last year, which indicates a negative year-over-year growth rate of 36.4%. The company is scheduled to announce its next earnings report on Tuesday, November 12th.
On average, analysts expect that Mediwound will report full year earnings of ($0.57) per share for the current year, with EPS estimates ranging from ($0.66) to ($0.51). For the next fiscal year, analysts anticipate that the firm will post earnings of ($0.54) per share, with EPS estimates ranging from ($0.63) to ($0.45). Zacks’ EPS averages are an average based on a survey of analysts that cover Mediwound.
Mediwound (NASDAQ:MDWD) last released its quarterly earnings data on Tuesday, August 13th. The biopharmaceutical company reported ($0.12) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.03. Mediwound had a net margin of 70.54% and a negative return on equity of 156.56%. The company had revenue of $20.75 million for the quarter, compared to analysts’ expectations of $7.03 million.
A number of research firms have weighed in on MDWD. Oppenheimer cut their price objective on shares of Mediwound from $15.00 to $7.00 and set an “outperform” rating on the stock in a report on Wednesday, August 14th. HC Wainwright initiated coverage on shares of Mediwound in a research report on Monday, August 5th. They set a “buy” rating and a $5.50 target price on the stock. Zacks Investment Research upgraded shares of Mediwound from a “sell” rating to a “hold” rating in a research report on Friday, July 12th. Finally, ValuEngine upgraded shares of Mediwound from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Mediwound currently has an average rating of “Buy” and an average target price of $7.25.
MDWD stock traded up $0.01 during midday trading on Tuesday, reaching $3.18. 15,760 shares of the company were exchanged, compared to its average volume of 37,251. The company has a debt-to-equity ratio of 0.11, a quick ratio of 3.99 and a current ratio of 4.13. Mediwound has a 1-year low of $2.55 and a 1-year high of $6.75. The stock’s 50-day simple moving average is $3.03 and its 200 day simple moving average is $4.03. The company has a market cap of $87.24 million, a price-to-earnings ratio of -6.49 and a beta of 0.51.
Several institutional investors and hedge funds have recently made changes to their positions in the company. Oppenheimer & Co. Inc. grew its position in shares of Mediwound by 6.5% during the first quarter. Oppenheimer & Co. Inc. now owns 32,800 shares of the biopharmaceutical company’s stock worth $164,000 after acquiring an additional 2,000 shares during the last quarter. Meitav Dash Investments Ltd. grew its position in shares of Mediwound by 0.6% during the first quarter. Meitav Dash Investments Ltd. now owns 598,508 shares of the biopharmaceutical company’s stock worth $2,993,000 after acquiring an additional 3,536 shares during the last quarter. Sargent Investment Group LLC grew its position in shares of Mediwound by 114.8% during the second quarter. Sargent Investment Group LLC now owns 29,000 shares of the biopharmaceutical company’s stock worth $98,000 after acquiring an additional 15,500 shares during the last quarter. Deutsche Bank AG grew its position in shares of Mediwound by 73.5% during the fourth quarter. Deutsche Bank AG now owns 39,740 shares of the biopharmaceutical company’s stock worth $161,000 after acquiring an additional 16,840 shares during the last quarter. Finally, Marshall Wace LLP purchased a new position in shares of Mediwound during the first quarter worth approximately $93,000. Institutional investors and hedge funds own 28.75% of the company’s stock.
MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products to address unmet needs. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns in the European Union, Israel, and Argentina.
Further Reading: Sell-Side Analysts
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Mediwound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mediwound and related companies with MarketBeat.com's FREE daily email newsletter.